UroGen Pharma (URGN) EBITDA Margin (2017 - 2026)

UroGen Pharma (URGN) has 10 years of EBITDA Margin data on file, last reported at 39.76% in Q1 2026.

• Quarterly EBITDA Margin rose 14249.0% year-over-year to 39.76% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 77.02% (up 4049.0% YoY) and the FY2025 annual result came in at 113.73%, down 667.0% from the prior year.
• EBITDA Margin rose to 39.76% in Q1 2026, from 50.52% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 39.76% in Q1 2026 to a low of 182.26% in Q1 2025.
• A 5-year average of 106.34% and a median of 112.36% in 2022 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2022 — EBITDA Margin surged 18701 bps — and 2025, when it slumped 5290 bps.
• Tracing URGN's EBITDA Margin over 5 years: stood at 112.1% in 2022, then jumped by 45 bps to 62.09% in 2023, then plunged by 81 bps to 112.59% in 2024, then soared by 55 bps to 50.52% in 2025, then rose by 21 bps to 39.76% in 2026.
• The last three EBITDA Margin figures came in at 39.76% (Q1 2026), 50.52% (Q4 2025), and 99.65% (Q3 2025), per Business Quant data.